Young-Jack Lee, CEO of the leading Korean CRO, LSK Global PS said, “For pharmaceutical companies, it is important to reduce risk in clinical trials because more than half from the drug development budget is invested” and added, “Worldwide, there is a new drug development related... (Article Link)